Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 33 Breast Neoplasms 26 Triple Negative Breast Neoplasms 17 Prostatic Neoplasms 16 Fallopian Tube Neoplasms 11 Neoplasms 9 Fanconi Anemia, Complementation Group D1 7 Endometrial Neoplasms 7 Pancreatic Neoplasms 6 Glioma 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Neoplasm Metastasis 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Carcinosarcoma 3 Carcinoma, Renal Cell 3 Wilms Tumor 2

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Immunotherapy × olaparib × Clear all

NCT04169841 2024-02-13

GUIDE2REPAIR

Centre Georges Francois Leclerc

Phase 2 Active not recruiting

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡